

## ASX Announcement

14 November 2022

### Results of 2022 Annual General Meeting

Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company**), is pleased to advise that shareholders of the Company passed all Resolutions (outlined in the table below) in the Notice of Meeting dated 14 October 2022 at the Annual General Meeting held today at 2:00pm (Sydney time) by way of poll.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA (2) of the *Corporations Act 2001* (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is **attached**.

This announcement has been approved for release by the Chairman of the Company.

#### For further information, please contact:

**James Graham** – Chief Executive Officer, +61 2 9256 2571

**Maggie Niewidok** – Company Secretary, +61 2 8072 1400



**ASX:** RCE, **FSE:** R9Q

**Head Office:** Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

# Disclosure of Proxy Votes

## Recce Pharmaceuticals Ltd

Annual General Meeting

Monday, 14 November 2022



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	16,786,414	15,607,210 92.98%	969,065 5.77%	67,158	210,139 1.25%	15,853,292 94.24%	969,065 5.76%	67,158
2 Re-election of Dr John Prendergast as Director	P	31,381,110	25,051,477 79.83%	6,081,686 19.38%	9,000	247,947 0.79%	57,713,678 90.47%	6,081,686 9.53%	9,000
3 Re-election of Alan W. Dunton, MD as Director	P	31,321,110	31,013,606 99.02%	59,557 0.19%	69,000	247,947 0.79%	63,675,807 99.91%	59,557 0.09%	69,000
4 Re-election of Alistair McKeough as Director	P	31,321,110	31,007,922 99.00%	65,241 0.21%	69,000	247,947 0.79%	63,670,123 99.90%	65,241 0.10%	69,000
5 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	31,347,551	29,839,519 95.19%	1,166,473 3.72%	42,559	341,559 1.09%	62,595,332 98.17%	1,166,473 1.83%	42,559
6 Adoption of New Constitution	P	31,235,341	24,380,388 78.05%	6,492,006 20.78%	154,769	362,947 1.16%	57,157,589 89.80%	6,492,006 10.20%	154,769
7 Approval of Issue of Options to Alistair McKeough, Director of the Company	P	16,754,993	13,814,758 82.45%	2,555,708 15.25%	98,579	384,527 2.29%	14,235,228 84.78%	2,555,708 15.22%	98,579



			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Approval to Increase the Maximum Aggregate Amount of Non-Executive Directors' Fees	P	16,513,952	13,567,082 82.16%	2,604,611 15.77%	81,001	342,259 2.07%	13,945,284 84.26%	2,604,611 15.74%	81,001

